The promise and pitfalls of molecular testing in oncology

Great strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain that frustrate both physicians and patients.

Tecentriq beats rivals to EU breast cancer market

NHS reimburses Roche's Hemlibra in new group of haemophilia ...

NHS England has agreed to reimburse Roche’s Hemlibra (emicizumab) in a new group of patients with haemophilia A, widening access to the potentially life-saving drug.

Roche's CMO Horning to retire, Lilly's high-flyer Garraway s...

Roche’s influential chief medical officer Sandra Horning is to retire at the end of the year, the company has confirmed, to be replaced by a high-flyer from rival Eli Lilly.

FDA approves Roche's "tumour agnostic" drug Rozlytrek

The FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in cancer, instead of where the disease originates. <

AZ's lung cancer drug Tagrisso gets boost from first line OS...

AstraZeneca has announced figures confirming that its Tagrisso extends overall survival in patients with untreated non-small cell lung cancer with certain mutations, compared with older alt